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Abstract
Background: Systemic sclerosis (SSc) is an autoimmune connective tissue
disease characterised by skin and internal organs fibrosis due to accumulation of
extra cellular matrix (ECM) proteins. Tissue inhibitor of metalloproteinases 1 (TIMP-
1) plays a key role in ECM deposition.
Aim: To investigate the role of miR-29a in regulation of TAB1-mediated TIMP-1
production in dermal fibroblasts in systemic sclerosis.
Methods: Healthy control (HC) and SSc fibroblasts were cultured from skin
biopsies. The expression of TIMP-1, MMP-1 and TGF-b activated kinase 1 binding
protein 1 (TAB1) was measured following miR-29a transfection using ELISA, qRT-
PCR, and Western Blotting. The functional effect of miR-29a on dermal fibroblasts
was assessed in collagen gel assay. In addition, HeLa cells were transfected with
39UTR of TAB1 plasmid cloned downstream of firefly luciferase gene to assess
TAB1 activity. HC fibroblasts and HeLa cells were also transfected with Target
protectors in order to block the endogenous miR-29a activity.
Results: We found that TAB1 is a novel target gene of miR-29a, also regulating
downstream TIMP-1 production. TAB1 is involved in TGF-b signal transduction, a
key cytokine triggering TIMP-1 production. To confirm that TAB1 is a bona fide
target gene of miR-29a, we used a TAB1 39UTR luciferase assay and Target
protector system. We showed that miR-29a not only reduced TIMP-1 secretion via
TAB1 repression, but also increased functional MMP-1 production resulting in
collagen degradation. Blocking TAB1 activity by pharmacological inhibition or TAB1
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knockdown resulted in TIMP-1 reduction, confirming TAB1-dependent TIMP-1
regulation. Enhanced expression of miR-29a was able to reverse the profibrotic
phenotype of SSc fibroblasts via downregulation of collagen and TIMP-1.
Conclusions: miR-29a repressed TAB1-mediated TIMP-1 production in dermal
fibroblasts, demonstrating that miR-29a may be a therapeutic target in SSc.
Introduction
Systemic sclerosis (SSc) is an autoimmune disease characterized by increased
production of collagen and other profibrotic factors, including tissue inhibitors of
metalloproteinases (TIMPs).
TIMPs and matrix metalloproteinases (MMPs) are responsible for maintaining
the balance between production and degradation of extracellular matrix proteins
(ECM). Fibroblasts play an essential role during pathological remodelling of ECM
by excessive deposition of collagen and TIMP-1 [1]. A previous study showed that
TIMP-1 is increased in SSc sera and is excessively produced by fibroblasts isolated
from the involved skin lesions of SSc patients [2, 3]. We have also demonstrated
that monocytes from SSc patients produce more TIMP-1 following TLRs
stimulation, thereby contributing to fibrosis development [4, 5]. In animal
models, the serum level of TIMP-1 correlates with dexamethasone-induced liver
fibrosis in rats. Likewise, TIMP-1 strongly promotes liver fibrosis development in
CCL4-treated TIMP-1 transgenic mice [6, 7]. Furthermore, adenoviral over-
expression of human recombinant TIMP-1 in murine fibroblasts increased their
proliferation and differentiation toward pathogenic myofibroblast phenotype,
which demonstrates an additional role of TIMP-1 beyond the inhibition of MMPs
activity [8].
Recently, it has been shown that the fibrotic remodelling process is associated
with an altered pattern of miRNAs expression. Micro RNAs (miRs) are small,
noncoding (consisting of 19 to 22 nucleotides) RNAs that mostly bind to 39UTRs
of target mRNAs leading to gene silencing. Thus, miRs act as a fine-tuner of gene
expression that negatively regulate between 25 and 60 percent of human protein-
coding genes [9]. Furthermore, expression of miRs can be altered under
conditions of pathophysiological stress or disease, allowing miRs to be important
biomarkers and attractive candidates for therapeutic manipulation [10, 11].
Recent studies have shown that miRs are involved in pathological fibrosis in many
organs including lung, heart, kidney and skin [12–14]. In particular, it has been
demonstrated that the family of miR-29 is a key regulator of skin fibrosis [15, 16].
The miR-29 family consists of three members (miR29-a, -b, -c) which bind to an
identical ‘seed’ sequence of transcript, therefore allowing the targeting of the same
genes [12]. Various computational algorithms predicted that miR-29 can target
multiple genes including ECM components such as collagen, fibrillin, elastin and
also TGF-b regulated genes, including TGF-b activated kinase 1/MAP3K7 binding
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protein 1 (TAB1) [17, 18]. Several of these genes have been already validated in
in vitro and in vivo approaches [17]. In particular, type 1 collagen was shown to
be a direct target gene of miR-29a [15, 19]. It was demonstrated that miR-29a
downregulated collagen expression in dermal fibroblasts, which resulted in
inhibition of ECM deposition. Furthermore, miR-29a was strongly reduced in SSc
fibroblasts compared to healthy controls suggesting an important role of this
microRNA as a biomarker of fibrogenesis [15].
TGF-b is thought to play a pivotal role in SSc pathogenesis via induction of
profibrotic molecules including collagen and TIMP-1 [20–22] and by reduction of
matrix proteases synthesis [23, 24]. In addition, TGF-b can downregulate miR-29
expression and therefore can indirectly promote ECM accumulation, which is
observed in lung and renal fibrosis [18, 25, 26]. Although TGF-b signals via
canonical SMAD-dependent pathways and by activation of TGF-b activated
kinase 1/MAP3K7 (TAK1) and its binding protein TAB1 [27], there is evidence
for a cross-talk and close interference between TAK1 and SMAD pathways upon
TGF-b stimulation [28, 29]. Importantly, the binding of TAB1 to TAK1 is
essential for TAK1 phosphorylation. TAK1 was shown to be constitutively
phosphorylated in fibroblasts isolated from skin lesions of SSc patients [30].
TAK1-deficient murine fibroblasts downregulated TIMP-3 expression, likewise
conditional TAK1 KO mice showed reduced dermal thickness and delayed wound
closure [30, 31]. These findings imply that TAB1/TAK1 complex plays a crucial
role in wound healing and fibrosis development. However, a detailed under-
standing is still lacking.
In the present study, we demonstrated the ability of miR-29a to prevent fibrosis
development in dermal fibroblasts via direct repression of its novel target gene
TAB1. This consequently leads to TIMP-1 downregulation and functional
collagen breakdown via MMP-1.
Methods
Compounds, reagents, and cell culture
Skin biopsy specimens were obtained by punch biopsies from HC and SSc
patients. The study was approved by the Health Research Authority (National
Research Ethics Service – Sunderland, ethical approval no. 13/NE/0089) and
written informed consent was obtained from all patients. Dermal fibroblasts were
cultured from skin biopsies as described before [32], and cultured in RPMI
(Invitrogen) supplemented with penicillin (100 units/ml), streptomycin (100 mg/
ml), L-glutamine (2 mM) (all Sigma) and 10% FSC 37 C˚ in atmosphere
containing 5% CO2. HeLa cells were cultivated with the same complete RPMI.
Additionally, serum-starved fibroblasts were treated with graded doses of (5Z)-7-
Oxozeanol (Tocris Science) (TAK-1 inhibitor) in the presence of 5 ng/ml human
recombinant TGF-b (Invitrogen) for 24 h to measure TIMP-1 secretion. Cell
viability following Oxozeanol treatment was determined using MTS assay
(Promega) according to the manufacturer’s recommendations.
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MMP-1, TIMP-1, collagen 1A1, TAB1 mRNA analysis
Total RNA from dermal fibroblasts was extracted using TRIzol reagent (Sigma),
according to the manufacturer’s instruction. 500 ng of RNA was reverse
transcribed to cDNA using random hexamers and moloney murine leukemia
virus reverse transcriptase enzyme (Invitrogen) according to the manufacturer’s
protocol. TIMP-1, collagen 1A1 (col1A1), TAB1, MMP-1 and ribosomal 18S
expression were analysed using SYBR Green mix. Samples were analysed in
triplicate and normalised to the 18S housekeeping gene using the AB7500
(Applied Biosystems) qRT-PCR machine and program. miR-29a expression was
normalised to SNORD-25 - endogenous small nuclear RNA control (TaqMan
MicroRNA Assays, Applied Biosystems). Relative expression levels to the average
healthy control were calculated using the following equation: (2- Delta Delta CT).
The sequence of following primers were used; col1A1: forward 59-CAA GAG GAA
GGC CAA GTC GAG G-39, reverse 59- CGT TGT CGC AGA CGC AGA T-39, 18S:
forward 59-GAA TGG CTC ATT AAA TCA GTT ATG G-39, reverse 59-TAT TAG
CTC TAG AAT TAC CAC AGT TAT CC-39, MMP-1: forward 59-AGT GAC TGG
GAA ACC AGA TGC TGA-39, reverse 59-GCT CTT GGC AAA TCT GGC CTG
TAA-39, TIMP-1: forward 59-GAC GGC CTT CTG CA ATT CC-39, reverse 59-
GTA TAA GGT GGT CTG GTT GAC TTC TG-39. TAB1: forward 59-ATG AGC
TCT TCC GTC TTT CG, reverse 59-ATC CCC ACC TGC TTG ATC T-39.
39UTR luciferase reporter assay
The full length of 39UTR of TAB1 was cloned downstream of firefly luciferase
plasmid under the control of SV40 promoter (True Clone, Human Collection,
OriGene). HeLa cells were co-transfected with 39UTR of TAB1 (300 ng) and
renilla plasmid (30 ng) using 1.5 ml of Fugene (Promega) transfection reagent.
The renilla construct was used to normalise transfection efficiency. Assays for
reporter gene activity were performed in duplicate according to Dual-luciferase
Pomega’s protocol and analysed using GloMax multi detection system (Promega).
Transfection experiments
HC or SSc dermal fibroblasts were transfected with synthetic precursor (pre-miR-
29, Thermo Scientific) or with negative control (cont-miR - anti-miR-67 Negative
Control no 1, Thermo Scientific) at a final concentration of 30 nM using Fugene
(Promega). The sequence of cont-miR was designed to be complementary to C.
elegans transcript, therefore should not interfere with human mRNA. 24 h after
transfection, cells were lysed and analysed for expression of type 1 collagen and
TIMP-1. In some experiments, HeLa cells or HC dermal fibroblasts were
transfected with 500 nM miScript Target protectors (Qiagen). Target protectors
were synthesised to be complementary to the seed and flanking regions of 39UTR
of TAB1 thus protecting the target (Table 1).
HC dermal fibroblasts were seeded into 24-well plate and transfected using
0.8 ml DharmaFECT transfection reagent (Thermo Scientific) with siRNA against
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TAB1 (on Target plus Smart pool, Thermo Scientific) or scramble oligo’s at a final
concentration of 100 nM. 48 h following transfection, cells were lysed to examine
TAB1 protein silencing.
Functional collagen assay
Collagen gels were prepared as described elsewhere [33]. Briefly, 56104 HC
dermal fibroblasts were seeded on the collagen gels (type 1 collagen from rat tail -
C8897, Sigma-Aldrich) and transfected with miR-29a, cont-miR or recombinant
TIMP-1 protein was added to the cultures. After 24 h, pictures were taken with
the Syngene G-Box imaging system and the gel area was calculated using Image J
software.
Western blot and ELISA analysis
Briefly, 56104 HC dermal fibroblasts were lysed using Laemmli sample buffer
(S3401, Sigma) and subsequently 15 ml of total cell lysates were separated by SDS
polyacylamide gel and electrophorised onto nitrocellulose membrane. To detect
proteins expression antibodies against human TIMP-1 (ab1827, Abcam), TAB1
(C25E9, Cell Signaling), GAPDH (ab9484, Abcam) and secondary HRP-
conjugated (Dako) antibody were used. TIMP-1 and MMP-1 (both R&D
Systems) protein concentration in culture supernatants were measured by ELISA
according to the manufacturer’s protocol. Signal development was performed
using HRP/Streptavidin and OPD substrate (Sigma-Aldrich) at room tempera-
ture. Fluorescence was measured using a plate reader (Tecan, Sunrise). Samples
were run in duplicate and serial dilution was performed in order to fall within the
detection limits of the assay (0–80 ng/ml).
Statistical and Computational analysis
All data are presented as mean¡SEM. The differences between the groups were
tested for their statistical significance by non-parametric two tailed T-test using
GraphPad Prism (GraphPad Software, San Diego, CA). A p value of less than 0.05
was considered statistically significant; p values are expressed as follows: ns for not
significant; 0.05.p.0.01 as*; 0.01.p.0.001 as**; p,0.001 as***. Computational
prediction analyses of mR-29a targeting TAB1 was performed by combining the
results of computational prediction algorithms provided by miRDB, miRanda and
TargerScanHuman 6.2. These are publically available target prediction databases.
Western blot quantification was performed using ImageJ software.
Table 1. Sequence of 39UTR of TAB1 to which Target protector is complementary (seed regions of 39UTR of TAB1 are highlighted in bold).
Name Target binding site sequence Seed region in 39UTR TAB1
region A 59-GCCTTGCATTTTCCTTCTGGTGCTGTGAAG-39 801–807
region B 59-TTCCAAGAATGCCTCTGTGGTGCTGTTTGG-39 1574–1580
doi:10.1371/journal.pone.0115596.t001
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Results
Repressed gene expression of type 1 collagen by miR-29a in HC
dermal fibroblasts
HC dermal fibroblasts were transfected with miR-29a or non-targeting control
miRNA (cont-miR) 6 and 24 h after transfection, the involvement of miR-29a in
ECM remodelling was determined. It is well known that collagen is a target gene
for miR-29a expression [15, 16] therefore, to assess the TIMP-1 expression in the
presence 30 nM of miR-29a, col1A1 expression was also measured to confirm
transfection efficiency of miR-29a. In Figs. 1A and 1B it can be seen that 6 h
following transfection, both col1A1 and TIMP-1 mRNA were not repressed by
miR-29a. However, miR-29a significantly inhibited col1A1 (p,0.001), but not
TIMP-1 mRNA after 24 h (Figs. 1A and 1B, respectively). This suggests that
col1A1, but not TIMP-1, is a direct target gene of miR-29a. Indeed, following
computational analysis we confirmed that the seed region of miR-29a does not
have the binding sites to 39UTR of TIMP-1 mRNA, suggesting that TIMP-1 is an
indirect target gene of miR-29a.
miR-29a repressed the level of TIMP-1 protein in HC dermal
fibroblasts
To further define miR-29a activity on the level of TIMP-1 protein, HC dermal
fibroblasts were transfected as previously with miR-29a, cont-miR and analysed
using ELISA and Western blot. It can be seen that 24 h, but not 6 h (Fig. 1C)
following miR-29a transfection, TIMP-1 secretion was significantly down-
regulated compared to untreated cells (p,0.05). Likewise, the level of TIMP-1
protein after 24 h was reduced upon miR-29a, but not in untreated or cont-miR
transfected HC dermal fibroblasts assessed by densitometry (Fig. 1D). These
findings imply that other protein(s) must be targeted and repressed by miR-29a
that also regulates TIMP-1 protein expression. We also found that TLR4 agonist
(LPS) induces TIMP-1 production (Fig. 1D), similarly to TLR4-mediated col1A1
induction, which was previously published by Bhattacharyya et al. [34].
miR-29a alters contractile properties of HC dermal fibroblasts
To measure the effect of miR-29a on contractile properties of fibroblasts, HC
dermal fibroblasts were transfected as previously and tested for contractile
properties in a collagen gel degradation assay. This assay is dependent on MMPs,
the activity of which results in disintegration of collagen structures [35–37]. HC
dermal fibroblasts transfected with miR-29a significantly increased gel degrada-
tion (Fig. 2A), as the area of collagen gels was reduced by 36% compared to HC
dermal fibroblasts transfected with cont-miR (Fig. 2B). We also showed that
MMP-1 expression was significantly increased at both the gene and protein level
in cells growing on collagen gels compared to HC dermal fibroblasts seeded on
standard tissue culture treated plastic (p,0.01) (Figs. 2C, 2D). Interestingly, HC
dermal fibroblasts cultured on collagen gels secreted higher level of MMP-1
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following miR-29a transfection compared to cont-miR, although the difference
did not reach statistical significance (Fig. 2D). In order to reduce MMP-1-
dependent collagen degradation, we added recombinant TIMP-1 to the media to
block catalytic activity of MMPs. As expected, the area of collagen gel was most
preserved upon TIMP-1 addition due to MMP-1 inactivation (Figs. 2B and 2D).
Furthermore, the level of secreted TIMP-1 significantly decreased in HC dermal
fibroblasts transfected with miR-29a compared to cont-miR or untreated cells
(p,0.001) (Fig. 2E). This suggests that miR-29a not only inhibited secretion of
TIMP-1 in HC dermal fibroblasts, but also functionally increased collagen gel
degradation by MMP-1 breakdown.
TAB1 as a novel target of miR-29a
We next investigated which gene(s) can be directly targeted by miR-29a, but can
also regulate the TIMP-1 signaling pathway. Following computational prediction
analyses using several miRNA target databases including miRDB, miRANDA,
HumanScan 6.2, we found that TAB1 has predicted miR-29a target sites. We
noticed that miR-29a not only binds to the two regions of 39UTR of TAB1, but
also that TAB1 is activated upon TGF-b [38], a key molecule triggering TIMP-1
Fig. 1. Levels of col1A1 and TIMP-1 mRNA and protein expression after miR-29a transfection. HC dermal fibroblasts were transfected with 30 nM miR-
29a, 30 nM non-targeting cont-miR or vehicle only (untr). Col1A1 (A) and TIMP-1 mRNA (B) and TIMP-1 protein secretion (C) were determined after 6 h and
24 h following transfection. TIMP-1 protein level was also determined after 24 h from transfection and following 1 mg/ml TLR4 agonists (LPS) treatment (D).
Densitometry analysis of three independent experiments of HC fibroblasts after 24 h from transfection was performed and GAPDH was used as a loading
control (D).
doi:10.1371/journal.pone.0115596.g001
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production [39]. This suggests that TAB1 might be a good candidate regulating
TIMP-1 in the presence of miR-29a. To validate this prediction in in vitro
experiments, we used a plasmid where 39UTR of TAB1 was cloned to firefly
luciferase construct and transfected into HeLa cells to achieve high transfection
efficiency (Fig. 3A), since primary HC fibroblasts were difficult to transfect with
exogenous DNA. We used renilla plasmid to normalise 39UTR-TAB1 plasmid
expression in cells transfected with miR-29a and cont-miR or control vehicle
(transfection reagent only). As seen in Fig. 3B, the activity of luciferase was
Fig. 2. Functional effect of miR-29a on contractile properties of HC fibroblasts. HC dermal fibroblasts were transfected with 30 nM miR-29a, 30 nM
cont-miR or stimulated with 100 ng/ml exogenous recombinant TIMP-1 and contractile properties of HC dermal fibroblasts were assessed after 24 h by
collagen degradation assay (A) and percentage of collagen gel area was measured (B). MMP-1 mRNA was measured in untreated HC dermal fibroblasts
cultivated on monolayers or seeded on collagen gel (C). Secreted MMP-1 level was measured in HC dermal fibroblasts cultivated on monolayers or seeded
on collagen gel in the presence of miR-29a, cont-miR or recombinant TIMP-1 (D). Similarly, TIMP-1 secretion was measured in HC dermal fibroblasts
seeded on collagen gel in the presence of miR-29a, cont-miR or vehicle only (untr) (E).
doi:10.1371/journal.pone.0115596.g002
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significantly decreased, which indicates miR-29a likely targets the 39UTR of TAB1
resulting in either degradation or inhibition of translation relative to control-miR.
Furthermore, we also tested which prediction seed (in position 801–807 refers to
A and in position 1574–1580 refer to B, Fig. 2A) plays a crucial role in TAB1
degradation by miR-29a. In order to validate this, we used Target protector’s
technique. The RNA sequences of Target protectors are perfectly complementary
to miR-29a seed of the 39UTR of TAB1 and their flanking regions. Thus, Target
protectors compete with endogenous miR-29a for seed sequence binding and
prevent miRNA/mRNA association due to higher affinity of Target protectors to
the TAB1 sequence. This consequently results in hindering gene repression by
miR-29a. HeLa cells co-transfected with both Target protectors and 39UTR of
TAB1 plasmid were able to significantly restore luciferase activity (Fig. 3C).
However, when HeLa cells were transfected with 39UTR of TAB1 plasmid and
individual Target protector (interfering with either seed A or B), the luciferase
activity was similar to control cells. This suggests that individual Target protector
was not efficient to prevent repression of luciferase activity by miR-29a via the
TAB1 39UTR degradation, due to the presence of other miR-29a binding sites.
Therefore, both Target protectors are required for TAB1 protection from further
Fig. 3. miR-29a binds to 39UTR of TAB1. HeLa cells were co-transfected with 300 ng 39UTR TAB plasmid (A) and 30 ng renilla construct in the presence of
30 nM miR-29a, 30 nM cont-miR or vehicle only (untr) (B). Similarly, HeLa cells were co-transfected with 39UTR TAB construct and renilla in the presence of
500 nM Target Protect binding to seed A - TP A, or seed B - TP B or both - TP A+B (C).
doi:10.1371/journal.pone.0115596.g003
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degradation by endogenous miR-29a in HeLa cells. Of note, the level of
endogenous miR-29a was enhanced in HeLa cells compared to HC dermal
fibroblasts (data not shown). Therefore, there was a rational use of HeLa cells
transfected with Target protector against endogenous miR-29a.
Target protectors promotes profibrotic phenotype in HC dermal
fibroblasts
In addition, to confirm that miR-29a directly decreases expression of TAB1, HC
dermal fibroblasts were transfected with miR-29a and 24 h later TAB1 gene and
protein expressions were measured. The expression of TAB1 mRNA was
significantly reduced following miR-29a transfection compared to cont-miR
(Fig. 4A). Based on densitometry, the level of TAB1 protein was also reduced
upon miR-29a transfection, but not in the presence of cont-miR (Fig. 4B). We
then asked if suppressing TAB1 degradation by miR-29a affects TIMP-1 secretion.
To test this, HC dermal fibroblasts were transfected with both or individual Target
protectors and TIMP-1 level was measured by ELISA. As seen previously on
luciferase assay, only the presence of both Target protectors allowed for significant
derepression of TIMP-1 secretion (p,0.001) (Fig. 4C). This suggests that both
putative sites of 39UTR of TAB1 need to hybridise to Target protectors in order to
prevent TAB1 degradation by endogenous miR-29a and to promote TIMP-1
production.
In addition, we have measured the basal level of TAB1 in HC and SSc
fibroblasts. Although it did not reach statistical significance due to limited
number of samples, it can be seen that SSc fibroblasts have 1.7 times higher
mRNA level of TAB1 compared to HC fibroblasts (Fig. 4D). We also noticed that
profibrotic IL-6 trans-signaling reduced endogenous level of miR-29a in HC
fibroblasts (data not shown). This suggests that IL-6 trans-signaling not only
promotes profibrotic phenotype via direct collagen and TIMP-1 induction
[40, 41], but also can act indirectly by reduction of miR29a levels.
TAK1/TAB1 inhibitor downregulates TIMP-1 secretion in TGF-b
stimulated HC dermal fibroblasts
We used the chemical agent – (5Z)-7-Oxozeanol (Oxo), which acts as a potent
inhibitor of TAB1/TAK1 complexes, to mimic TAB1 downregulation by miR-29a.
In particular, Oxo blocks the ATP binding site required for TAK1 kinase activity
[42, 43]. Indeed, TIMP-1 secretion was suppressed in the presence of graded doses
of Oxo in TGF-b stimulated fibroblasts (Fig. 5A). A concentration of 2 mM of
Oxo was the most optimal for TIMP-1 inhibition, but also to keep cells viable, as
determined by MTS assay (Fig. 5C). Therefore, we used this concentration in
subsequent experiments to measure TIMP-1 mRNA (Fig. 5B). As expected,
TIMP-1 mRNA was strongly downregulated in the presence of Oxo in TGF-b
stimulated HC dermal fibroblasts. In addition, we measured the level of TIMP-1
in HC dermal fibroblasts transfected with siRNA against TAB1. 48 h following
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TAB1 knockdown by specific siRNA, confirmed by Western Blotting (Fig. 5E), the
level of TIMP-1 protein was reduced (Fig. 5D). Importantly, the level of TIMP-1
in HC dermal fibroblasts transfected with scramble oligos was comparable to
control cells. Overall, this implies that blocking TAB1/TAK1 complex activity,
either by pharmacological inhibition with Oxo or TAB1 knockdown by siRNA,
represses TIMP-1 secretion.
miR-29a reverses phenotype of SSc dermal fibroblasts
Firstly, to confirm the profibrotic phenotype of SSc fibroblasts the levels of col1A1
mRNA and secreted TIMP-1 in untreated HC and SSc fibroblasts were measured.
As seen in Fig. 6A the basal level of col1A1 mRNA was significantly elevated
(p50.0029) in SSc fibroblasts compared to HC. Also secreted TIMP-1 was 1.27
times higher in untreated SSc fibroblasts than HC (Fig. 6C). Finally, we analysed if
miR-29a is able to reverse the fibrotic phenotype of SSc dermal fibroblasts. As a
positive control for col1A1 and TIMP-1 induction, we stimulated SSc dermal
fibroblasts with TGF-b a potent pro-fibrotic cytokine (Figs. 6B and 6C). Indeed,
SSc dermal fibroblasts produced more col1A1 and TIMP-1 upon TGF-b
treatment. In contrast, miR-29a transfection reduced both col1A1 expression and
TIMP-1 secretion. This miR-29a-mediated suppression was specific, as transfec-
Fig. 4. Target protectors induce profibrotic phenotype in HC dermal fibroblasts. HC dermal fibroblasts were transfected with 30 nM miR-29a, 30 nM
cont-miR and TAB1 mRNA (A) and protein (B) expression were measured after 24 h. In addition, HC dermal fibroblasts were stimulated with 5 ng/ml TGF-b
as a positive control for TIMP-1 induction. Densitometry analysis of four independent experiments was performed and GAPDH was used as a loading control
(B). HC dermal fibroblasts were transfected with 500 nM TPA, TP B, or both TPA+B and TIMP-1 secretion was measured after 24 h (C). The basal level of
TAB1 mRNA in HC and SSc fibroblasts (D).
doi:10.1371/journal.pone.0115596.g004
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tion with cont-miR did not have any effect on col1A1 and TIMP-1 synthesis.
Overall, based on the above results and previously published findings we
hypothesise that the level of miR-29a is reduced in SSc dermal fibroblasts
compared to healthy controls due to upregulation of negative regulator of miR-
29a including TGF-b and IL-6 trans-signaling [15]. As a consequence of miR-29a
reduction, there is excessive production and activation of its target genes such as
col1A1 and TAB1. This leads to uncontrolled matrix protein deposition due to
increased synthesis of TIMP-1 and ultimately fibrosis progression (Fig. 6D).
Fig. 5. TAK1/TAB1 inhibitor downregulates TIMP-1 secretion in TGF-b stimulated HC dermal
fibroblasts. HC dermal fibroblast were pre-treated for 2 h with graded doses of Oxozeanol (TAK1/TAB1
inhibitor) prior to TGF-b stimulation (5 ng/ml) and TIMP-1 secretion and mRNA level were measured (A, B). To
assess viability of HC dermal fibroblasts upon 2 mM Oxozeanol treatment, MTS assay was performed (C). HC
dermal fibroblasts were transfected with 100 nM siRNA against TAB1 or scrambled oligos and TAB1 protein
and TIMP-1 secretion were analysed after 48 h from knockdown (D, E).
doi:10.1371/journal.pone.0115596.g005
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Fig. 6. miR-29a reverses phenotype of SSc dermal fibroblasts. The basal level of col1A1 was compared
between HC and SSc fibroblasts (A). SSc dermal fibroblasts were transfected with 30 nM miR-29a, 30 nM
cont-miR or stimulated with 5 ng/ml TGF-b and col1A1 mRNA level was measured (B). HC and SSc dermal
fibroblasts were transfected with 30 nM miR-29a, 30 nM cont-miR or stimulated with 5 ng/ml TGF-b and
secreted TIMP-1 was measured (C). Schematic representation of the role of miR-29a in ECM regulation via
TAB1 and TIMP-1 suppression in HC and SSc dermal fibroblasts (D). Enhanced activation of TGF-b signaling
in SSc dermal fibroblasts compared to HC fibroblasts results in downregulation of miR-29a, which leads to
increased expression of miR-29a target gene - TAB1.
doi:10.1371/journal.pone.0115596.g006
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Discussion
SSc is an autoimmune connective tissue disease characterised by fibrosis of skin
and internal organs due to accumulation of ECM proteins that consequently leads
to organ failure and premature death. Epigenetics is a way of regulating gene
expression without a change in the DNA base, which is mostly represented by
DNA-methylation, histone modification and miRNA regulation. Emerging
evidence suggests a role of miR-29a in SSc and several fibrotic diseases [15, 16],
due to its repression of ECM-associated genes like collagen and profibrotic growth
factors and their receptors [16, 18, 25].
In the present study, we demonstrated a novel role of miR-29a in fibrogenesis
by direct TAB1 targeting resulting in TIMP-1 downregulation. In particular, we
showed that TAB1 is a novel bona fide target gene of miRNA-29 based on
computational algorithms and TAB1 39UTR luciferase assay. In addition, we
showed for the first time that TAB1 regulates TIMP-1 production. It was
confirmed by epigenetic (miR-29a and siRNA of TAB1) and chemical (Oxo)
approaches, which blocked TAB-1 mediated signaling pathway. Consequently,
this resulted in TIMP-1 downregulation, functional collagen degradation and
reversal of the profibrotic phenotype of SSc fibroblasts. We also performed a
computational analysis which suggests that miR-29a can target 39UTRs of potent
inducers of TIMP-1 including TGF-b2, platelet-derived growth factor subunit B
(PDGFB), PDGF subunit C (PDGFC), PDGF receptor subunit B (data not
shown). Thus, miR-29a can impact TIMP-1 on multiple different steps.
Firstly, we showed that HC dermal fibroblasts transfected with miR-29a were
able to directly reduce col1A1 mRNA and indirectly decrease level of TIMP-1
protein. This TIMP-1 reduction also resulted in an imbalanced ratio between
TIMP-1 and MMP-1, in favour of MMP-1. We showed that miRNA-29a-
mediated inhibition of TIMP-1 leads to functional collagen breakdown via
upregulation of MMP-1 in dermal fibroblasts and therefore prevents matrix
protein deposition. The role of miRs in collagen gel disintegration has been also
demonstrated by Luna et al [44]. They showed that human trabecular meshwork
primary cells transfected with miR-200c increased collagen gel area, due to miR-
200c-mediated repression of the main contraction genes including endothelin A
receptor and RhoA kinase.
To further elucidate the mechanism of miR-29a-mediated repression of TIMP-
1, we used a computational approach to select the best candidate, which could be
a target gene of miR-29a and simultaneously regulate TIMP-1 synthesis. Indeed,
we found that miR-29a can bind to two seed regions of TAB1 transcript, but also
TAB1 is involved in signal transduction upon TGF-b stimulation, a key molecule
triggering TIMP-1 production. To address this hypothesis in in vitro settings, we
used 39UTR of TAB1 construct that was cloned downstream of firefly luciferase
gene and we showed that luciferase activity was decreased by 20 percent in the
presence of exogenous miRNA-29a, but not in the presence of control miRNA.
However, using specifically designed Target protectors, which block the
interaction between endogenous miR-29a and TAB1 transcript due to their higher
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binding affinity, left TAB1 unaffected. The modified backbone of Target
protectors increases their stability and prevents 39UTR of TAB1 from being loaded
into the RNA-induced silencing complex (RISC) and triggering an RNAi response
[45]. This was represented by increased luciferase activity in HeLa cells.
Importantly, blocking of both seed regions by Target protectors was essential to
prevent TAB1 degradation, as the individual seed interference did not rescue
39UTR of TAB1 to be degraded. Furthermore, HC dermal fibroblasts treated with
both Target protectors were able to block endogenous miR-29a interaction with
TAB1 resulted in increased secretion of TIMP-1 and thereby in promoting
pathogenic phenotype in HC dermal fibroblasts. This gain of function approach
strongly suggests that miR-29a binds to both putative sites of 39UTR of TAB1 and
simultaneously plays a role in TIMP-1 regulation.
One of the major kinases involved in the TGF-b signaling cascade is TAK1 and
TGF-b is important in fibrosis. It is known that binding of TAB1 is required for
TAK1 phosphorylation and further signal transduction [43]. Downstream
signaling of TAB1/TAK1 complex plays a central role in regulating MAPK
pathways, which subsequently activates several transcription factors. It was shown
that NF-kB and activation protein 1 (AP-1) transcription factors respond to
TAK1/TAB1 activation and consequently induce proinflammatory and profibrotic
genes expression [46]. In particular, it was found that ectopic expression of AP-1
family members resulted in increased expression of TIMP-1 and matrix proteins,
suggesting that downstream AP-1 activation is important in TIMP-1 expression
and contributes to fibrosis development [47, 48]. However, a clear understanding
whether activation of this complex directly leads to TIMP-1 expression is still
lacking. In the present study we found that TAB1/TAK1 signaling pathway is
involved in regulation of TIMP-1 expression. To confirm that SMAD-
independent pathway plays a role in TIMP-1 expression, HC dermal fibroblasts
were treated with chemical inhibitor (Oxo) blocking TAK1 activity. As expected,
Oxo inhibited TIMP-1 synthesis on both protein and gene levels after TGF-b
stimulation. Likewise, HC dermal fibroblasts transfected with siRNA against
TAB1 secreted less TIMP-1 following TAB1 siRNA ‘knockdown’. Thus, blocking
of TAB1/TAK1 signaling will provide the basis for development more specific
targets which will neutralise the effects of TGF-b. Finally, SSc dermal fibroblasts
treated with miR-29a displayed an attenuated profibrotic phenotype by down-
regulation of col1A1 and TIMP-1 when compared to untreated SSc dermal
fibroblasts. This data provides an additional aspect that miR-29a is a central
player in fibrogenesis in dermal fibroblasts. It is important to remember that SSc
fibroblasts have intrinsically reduced levels of miR29a [49]. Molecules that can
enhance the expression of miR29a may be useful in reducing the fibrotic response.
Conclusion
Overall, in the present study, we found that miR-29a directly repressed its novel
target gene - TAB1 in dermal fibroblasts, which results in decreased TIMP-1 and
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increased functional MMP-1 secretion. In contrasts, enhanced expression of miR-
29a was able to reverse the profibrotic phenotype of SSc fibroblasts, thus
highlighting the potential role of miR-29a in SSc and fibrogenesis in general.
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